| Chromavision Medical Systems, Inc. | |||
| Proposed Ticker: | CVSN | 33171 Paseo Cerveza | |
| Exchange: | NASDAQ-National Market | San Juan Capitstrano, CA 92675 | |
| Industry: | Manufacturing (SIC Code 3826) | (888) 776-4276 | |
| Type of Shares: | Common Shares | Filing Date: | 4/30/97 | |
| U.S. Shares Filed: | 6,400,000 | Filing Price: | $5.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $32,000,000 | |
| Primary Shares: | 6,020,000 | Expenses: | - | |
| Secondary Shares: | 380,000 | Shares Out After: | 17,147,393 | |
| Spin out parent firm: | Safeguard Scientifics, Inc. | |||
| Manager | Tier | Phone |
| Robert W. Baird & Company | Lead Manager | (414) 765-3632 |
| Adams, Harkness & Hill | Co-manager | (617) 371-3705 |
| Issuer's Law Firm: | Biddle & Reath LLP |
| Bank's Law Firm: | Morgan, Lewis & Bockius |
| Auditor: | KPMG Peat Marwick |
| Registrar/Transfer Agent: | ChaseMellon Shareholder Services, L.L.C. |
Dollar amounts in U.S. millions except for per share data | |||||
| 3 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 3/31/97 | 3/31/96 | 3/31/97 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $1.19 |
| Net Income: | -$4.41 | -$1.41 | -$0.38 | Curr Assets: | |
| EPS: | -$0.36 | -$0.11 | -$0.20 | Liabilities: | $3.25 |
| Prior EPS: | -$1.92 | -$0.15 | Curr Liabilities: | ||
| Cash Flow/Oper: | -$7.06 | Equity: | -$2.06 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company has developed an automated intelligent microscope system that uses the company's proprietary imaging technologies for a wide variety of diagnostic and research applications. The company currently markets to research centers and intends to introduce to the healthcare market its system, the ChromaVision Digital Analyzer. The ChromaVision Digital Analyzer is designed to identify cells with specific characteristics within a sample of cells by detecting color produced by the reaction between common laboratory reagents and the cells. The ChromaVision Digital Analyzer uses proprietary imaging software and technology to capture digital images of cell samples and to detect the presence, count the number and measure the color intensity of cells containing a particular stain. The ChromaVision Digital Analyzer offers substantial flexibility because the software can be configured to identify different stains, thereby allowing the system to be adapted for use with different reagents to identify a broad range of target cellular conditions. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay outstanding debt, for the further development of the ChromaVision Digital Analyzer, including the financing of clinical trials and certain pre-marketing activities, for working capital, for general corporate purposes and for capital expenditures. |